Trump defends crypto legislation at private event featuring boxer Mike Tyson, Te...
President Donald Trump, at a Mar-a-Lago gathering of investors in his self-branded memecoin, said crypto is mainstream and banks s...
Dogecoin Eyes Breakout as Macro Cycle Pattern Aligns With Key Market Levels
TLDR: Dogecoin remains within Cycle 3 structure, reflecting past patterns of accumulation before major breakout phases Traders wat...
Next Crypto to Explode in 2026: Pepeto Tops the Board as Solana Hosts Tokenized...
The next crypto to explode in 2026 is narrowing fast as the April board tightens around two developments, with Bitget launching a...
TRUMP Token Insiders Allegedly Dump $46M Worth of Tokens Amid Supply Concentrati...
TLDR: Over 15.54M TRUMP tokens worth roughly $46M were sent to OKX by team-linked wallets over three weeks. A splitter wallet brok...
XRP Whale Outflow Dominance Climbs To 2024 Levels —Price To Follow?
The XRP price seems to have encountered significant resistance to its growth over the week. As of Wednesday, April 22, the cryptoc...
BlackRock’s bitcoin ETF just hit a massive milestone that proves crypto is now a...
IBIT options open interest topped Deribit on Friday, signaling rapid institutional adoption of regulated crypto derivatives in the...
Bitcoin Price Prediction: Metaplanet Raises $50 Million to Buy More BTC
Metaplanet raises $50M via zero-interest bonds for its 20th BTC purchase round. What does it mean for Bitcoin price? The post Bit...
Solana Foundation Lends USDT to Aave in DeFi Recovery Push, Plans AAVE Integrati...
TLDR: Solana Foundation is lending USDT to Aave for the first time to support the protocol’s ongoing recovery effort. Foundation...
Advanced Micro Devices (AMD) vs Intel (INTC): Top Chip Stock for 2025
AMD hit record $34.6B revenue in 2025 vs Intel's flat $52.9B. Compare analyst ratings, data center growth, and which chip stock fi...
CRISPR Therapeutics (CRSP) Stock Plunges 11% Amid Earnings Disappointment and Co...
CRISPR Therapeutics (CRSP) stock dropped 11% after missing Q1 estimates badly. Regeneron's free gene therapy approval adds pressur...